Navoximod

This product is for research use only, not for human use. We do not sell to patients.

Navoximod
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
250mg$1600Check With Us
500mg$2400Check With Us
1g$3600Check With Us

Cat #: V3268 CAS #: 1402837-78-8 Purity ≥ 98%

Description: Navoximod (formerly known as IDO-IN-7; NLG-1488; NLG919) is a potent inhibitor of the IDO (indoleamine-(2,3)-dioxygenase) pathway (Ki/EC50 = 7 nM/75 nM) with potential immunomodulating and antineoplastic activities.

References: Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)316.38
Molecular FormulaC18H21FN2O2
CAS No.1402837-78-8
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: > 10mMr
Water: N/Ar
Ethanol: N/A
SMILES CodeO[C@@H]([C@H]1CC[C@H](O)CC1)C[C@@H](C2=C3C=CC=C2F)N4C3=CN=C4
SynonymsNLG-1488; IDO-IN-7; NLG 1488; IDOIN7; NLG1488; Navoximod; IDO IN 7
ProtocolIn VitroUsing IDO-expressing human monocyte-derived dendritic cells (DCs) in allogeneic mixed lymphocyte reaction (MLR) reactions, Navoximod (NLG919) potently blocks IDO-induced T cell suppression and restores robust T cell responses with an ED50=80 nM. Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, Navoximod abrogates IDO-induced suppression of antigen-specific T cells (OT-I) in vitro, with ED50=120 nM.
In VivoVNavoximod (NLG919) is orally bioavailable (F>70%); and has a favorable pharmacokinetic and toxicity profile. In mice, a single oral administration of Navoximod reduces the concentration of plasma and tissue Kyn by ~50%. In vivo, in mice bearing large established B16F10 tumors, administration of Navoximod markedly enhances the anti-tumor responses of naïve, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA. In this stringent established-tumor model, Navoximod plus pmel-1/vaccine produce a dramatic collapse of tumor size within 4 days of vaccination (~95% reduction in tumor volume compare to control animals receiving pmel-1/vaccine alone without Navoximod).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM3.1608 mL15.8038 mL31.6076 mL63.2151 mL
5mM0.6322 mL3.1608 mL6.3215 mL12.6430 mL
10mM0.3161 mL1.5804 mL3.1608 mL6.3215 mL
20mM0.1580 mL0.7902 mL1.5804 mL3.1608 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.